CoChat

Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders

Muehlan, Clemens, Vaillant, Cedric, Zenklusen, Isabelle, Kraehenbuehl, Stephan, Dingemanse, Jasper · 2020 · Expert Opinion on Drug Metabolism & Toxicology
Cited by 102

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: The last two decades have witnessed a rapid increase in the knowledge about the role of the orexin system, particularly in the regulation of wakefulness and arousal. Dual orexin receptor antagonists (DORAs) have been approved for the treatment of insomnia disorders (suvorexant, lemborexant) and drugs with a distinctive profile (daridorexant) or orexin-2 receptor selectivity (seltorexant) are in development. AREAS COVERED: This review discusses pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and safety properties of orexin receptor antagonists (ORAs). EXPERT OPINION: In general, the drugs described have a similar effect on sleep characteristics although their pharmacokinetic variables differ. ORAs have the potential to revolutionize the pharmacological treatment of insomnia because they not only improve sleep, but, in addition, appear to have no dependence - and tolerance-inducing effects, which makes them suitable for long-term-treatment. The safety and tolerability profile of ORAs clearly differ from those of more traditional sleep-promoting drugs. Further research is needed to demonstrate benefits to patients suffering from insomnia disorder, e.g., with respect to improving not only sleep but also daytime functioning. In addition, ongoing and future research will show whether ORAs may have beneficial effects in patients with various psychiatric and neurodegenerative disorders, including Alzheimer's disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/17425255.2020.1817380

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Research works printed but not linked: 114

  1. 10.1007/s11065-011-9156-z · DOI
  2. 10.5665/SLEEP.1150 · DOI · Paper page
  3. 10.1176/appi.books.9780890425596 · DOI · Paper page
  4. 10.1016/S1474-4422(15)00021-6 · DOI · Paper page
  5. 10.1016/S1474-4422(13)70311-9 · DOI
  6. State-of-the-Science Conference NIH, 2005, NIH Cons State Sci Statements, 22, 1
  7. Insomnia RT, 2007, J Clin Sleep Med, 3, 7
  8. 10.3109/09540261.2014.888990 · DOI
  9. 10.1016/j.sleep.2010.02.018 · DOI · Paper page
  10. 10.1093/sleep/16.3.226 · DOI · Paper page
  11. Zammit GK, 1999, Sleep, 22, 379
  12. Balter MBUE, 1991, J Clin Psychiatry, 52, 16
  13. 10.1161/CIRCULATIONAHA.113.004500 · DOI · Paper page
  14. 10.1056/NEJMcp1412740 · DOI · Paper page
  15. 10.1016/j.sleh.2018.05.008 · DOI
  16. Benca RM, 2004, J Clin Psychiatry, 65, 26
  17. 10.7326/M15-1782 · DOI · Paper page
  18. Pigeon WR, 2007, J Clin Sleep Med, 3, 73
  19. 10.4088/PCC.v09n0105 · DOI · Paper page
  20. Holbrook AM, 2000, CMAJ, 162, 225
  21. Borbély AA, 1985, Hum Neurobiol, 4, 189
  22. Achermann P, 1987, Hum Neurobiol, 6, 203
  23. Taylor S, 2019, Public Health England, 89
  24. 10.5664/jcsm.26525 · DOI
  25. 10.1002/hup.594 · DOI · Paper page
  26. 10.1016/j.clinthera.2014.09.017 · DOI · Paper page
  27. 10.1016/j.sleep.2013.11.788 · DOI · Paper page
  28. 10.2165/00003495-200868130-00011 · DOI
  29. 10.4137/JCNSD.S1611 · DOI
  30. 10.5665/SLEEP.1272 · DOI · Paper page
  31. 10.4088/JCP.v69n1005 · DOI · Paper page
  32. 10.1016/S0166-2236(00)01594-0 · DOI · Paper page
  33. 10.3389/fnmol.2018.00220 · DOI · Paper page
  34. 10.1007/s40263-012-0036-8 · DOI
  35. 10.1038/nn.3810 · DOI · Paper page
  36. 10.1113/jphysiol.2011.217000 · DOI · Paper page
  37. 10.1016/j.neuron.2011.08.027 · DOI · Paper page
  38. 10.1111/j.1748-1716.2009.02056.x · DOI
  39. 10.1093/sleep/27.5.851 · DOI · Paper page
  40. 10.1378/chest.14-1617 · DOI · Paper page
  41. 10.1016/j.npep.2013.10.009 · DOI
  42. 10.1038/nm1544 · DOI · Paper page
  43. 10.1038/clpt.2010.19 · DOI
  44. 10.1038/clpt.2011.370 · DOI · Paper page
  45. 10.1016/S0304-3940(03)00066-1 · DOI
  46. 10.1371/journal.pone.0039131 · DOI · Paper page
  47. 10.1002/cmdc.201300003 · doi:10.1002/cmdc.201300003
  48. 10.1124/jpet.109.152009 · DOI · Paper page
  49. 10.3389/fnins.2014.00028 · DOI
  50. 10.1124/jpet.115.225466 · DOI
  51. 10.1177/0269881118773745 · DOI
  52. 10.1016/S0306-4522(01)00512-7 · DOI · Paper page
  53. 10.1523/JNEUROSCI.1887-05.2005 · DOI · Paper page
  54. 10.1021/jm100541c · DOI · Paper page
  55. 10.1111/ijcp.12568 · DOI · Paper page
  56. 10.3109/00498254.2015.1129565 · DOI
  57. 10.1002/jcph.785 · DOI
  58. 10.1002/cpt.1046 · DOI
  59. 10.1212/WNL.0b013e31827688ee · DOI · Paper page
  60. 10.1016/j.biopsych.2014.10.003 · DOI · Paper page
  61. 10.1016/S1474-4422(14)70053-5 · DOI · Paper page
  62. 10.1016/j.sleep.2015.10.007 · DOI
  63. 10.1016/j.sleep.2017.05.009 · DOI
  64. 10.5665/sleep.5168 · DOI
  65. 10.1007/s00213-016-4375-x · DOI · Paper page
  66. 10.1002/alz.12035 · DOI · Paper page
  67. 10.1093/sleep/zsz067.372 · doi:10.1093/sleep/zsz067.372
  68. 10.1017/cts.2018.167 · doi:10.1017/cts.2018.167
  69. 10.1089/cap.2019.0029 · DOI
  70. 10.1002/ams2.368 · DOI
  71. Hatta K, 2020, J Clin Psychiatry, 81, 19m12865
  72. 10.1007/s10388-017-0570-z · doi:10.1007/s10388-017-0570-z
  73. Toi N, 2019, J Clin Transl Endocrinol, 15, 37
  74. 10.1111/jch.13505 · DOI
  75. 10.1007/s40265-020-01276-1 · DOI
  76. Pastino G, 2015, Sleep, 38, A221
  77. 10.5664/jcsm.6800 · DOI · Paper page
  78. Thein SG, Alzheimer’s Assoc Int Conf 2019 July, 14–18
  79. Rosenberg R, 2019, JAMA, 2, e1918254
  80. 10.1016/j.sleep.2019.11.736 · doi:10.1016/j.sleep.2019.11.736
  81. 10.1017/S1092852920000802 · doi:10.1017/s1092852920000802
  82. Moline M, 2019, Sleep, 42, A150
  83. Eisai Co. Ltd. Eisai to present new 12-month safety & effectiveness data from phase 3 lemborexant SUNRISE 2 study and new patient and cohabitant insights about insomnia and toll on next-Day functioning at World Sleep Congress [Press release]. 2019 Sep 19.
  84. 10.1093/sleep/zsy260 · DOI · Paper page
  85. Zeitzer JM, 2020, JAMA, 3, e206614
  86. 10.5664/jcsm.8294 · DOI
  87. 10.1124/jpet.117.241596 · DOI
  88. 10.2174/1389200220666190206141814 · doi:10.2174/1389200220666190206141814
  89. 10.1016/j.euroneuro.2019.05.009 · DOI
  90. 10.1177/0269881119882854 · DOI
  91. 10.1097/JCP.0000000000001182 · DOI
  92. 10.1007/s00228-018-2559-5 · DOI
  93. 10.1111/1440-1681.13370 · DOI
  94. 10.1212/WNL.0000000000009475 · DOI
  95. 10.1002/ana.25680 · DOI
  96. Ltd I. Idorsia announces positive results in the first Phase 3 study of daridorexant with improved overall sleep and daytime performance of patients with insomnia [Press release]. 2020 Apr 20.
  97. 10.1177/0269881118791521 · DOI
  98. 10.1177/0269881118822258 · DOI
  99. 10.1038/s41398-019-0553-z · DOI · Paper page
  100. Minerva Neurosciences. Minerva Neurosciences announces achievement of primary and key secondary objectives in phase 2b clinical trial of seltorexant (MIN-202) in insomnia [Press release]. 2019 Jun 24.
  101. 10.1177/1715163514543856 · DOI
  102. 10.1046/j.1365-2125.1998.00764.x · DOI · Paper page
  103. 10.1001/jama.290.11.1500 · DOI · Paper page
  104. Dayal S, 2019, Clin Pharmacol Ther, 105, S.54
  105. 10.5664/jcsm.5382 · DOI
  106. 10.1002/kjm2.12130 · DOI
  107. Boof ML, Fietze I, Lederer K, et al. Effect of multiple-dose treatment with daridorexant on nighttime respiratory function in patients with mild and moderate obstructive sleep apnea (OSA). abstract #3058. ERS International Congress 2020. 2020. · doi:10.1183/13993003.congress-2020.2149
  108. 10.1093/sleep/30.3.312 · DOI · Paper page
  109. 10.2165/00003495-200363040-00004 · DOI
  110. 10.1016/j.rmed.2014.12.010 · DOI
  111. Boof ML, J Sleep Res, 2020
  112. 10.1093/sleep/zsz302 · DOI
  113. 10.1038/nm0507-526 · DOI
  114. 10.1038/s41386-020-0619-x · DOI

Cited by

See all 102

Metadata

Authors
Muehlan, C., Vaillant, C., Zenklusen, I., Kraehenbuehl, S., & Dingemanse, J.
Venue
Expert Opinion on Drug Metabolism & Toxicology
Published
2020-10-04
Volume
16
Issue
11
Pages
1063-1078
ISSN
  • 1742-5255 (ISSN-L)
  • 1744-7607
OpenAlex
W3084068073
Cited by
102
References
25
FWCI
11.34
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders. https://app.cochat.ai/papers/10.1080/17425255.2020.1817380
The paper
Muehlan, C., Vaillant, C., Zenklusen, I., Kraehenbuehl, S., & Dingemanse, J. (2020). Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders. Expert Opinion on Drug Metabolism & Toxicology. https://doi.org/10.1080/17425255.2020.1817380

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.